Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes

Patient Preference and Adherence

Volumn 2, Issue , 2008, Pages 323-332

  Philis Tsimikas, Athena ^a  

^a Whittier Institute for Diabetes   (United States)

Author keywords

Basal insulin; Insulin detemir; Modern analog; Type 2 diabetes mellitus

Indexed keywords

EID: 84877845681     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S3293     Document Type: Review

References (47)

1. Bock G., Wutte A, Köhler G, et al. 2008. Pharmacodynamics and pharmacokinetics of the long-acting insulin analogues detemir and glargine after 7 days of use and after their first administration in subjects with type 1 diabetes. [abstract] Diabetologia, 51(Suppl 1):S390.
2. Buchanan T.A. 2003. Pancreatic beta-cell loss and preservation in type 2 diabetes. Clin Ther, 25(Suppl B2):B32-B46.
3. Casella S. J, Mongilio MK, Plotnick LP, et al. 1993. Accuracy and precision of low-dose insulin administration. Pediatrics, 91(6):1155-7
4. Claxton A. J, Cramer J, Pierce C. 2001. A systematic review of the associations between dose regimens and medication compliance. Clin Ther, 23(8):1296-310.
5. Davies M. 2004. The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges. Int J Obes, 28(Suppl 2):S14-S22.
6. Dornhorst A., Lüddeke HJ, Koenen C, et al. 2008b. Transferring to insulin detemir from NPH insulin or insulin glarhine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE. Diabetes Obes Metab, 10:75-81.
7. Dornhorst A., Lüddeke HJ, Sreenan S, et al. 2007. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract, 61:523-8.
8. Dornhorst A., Lüddeke H-J, Sreenan S, et al. on behalf of the PREDICTIVE study group. 2008a. Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE™ study. Int J Clin Pract, 62(4):659-65.
9. Garber A., Calusen P, Pederson C, et al. 2007. Lower risk of hypoglycaemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: A pooled analysis of phase III trials. J Am Geriatr Soc, 55:1735-40.
10. Gough S.C. 2007. A review of human and analogue insulin trials. Diabetes Res Clin Pract, 77:1-15.
11. Haak T., Tiengo A, Draeger E, et al. 2005. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab, 7:56-64.
12. Havelund S., Plum A, Ribel U, et al. 2004. The mechanism of protraction of insulin detemir, a long-acting, acylated analogue of human insulin. Pharm Res, 21(8):1498-504.
13. Heise T., Nosek L, Ronn BB, et al. 2004. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes, 53(6):1614-20.
14. Heise T., Pieber TR. 2007. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab, 9:648-5.
15. Heller S., Kozlovski P, Kurtzhals P. 2007. Insulin's 85th anniversary. An enduring medical miracle. Diabetes Res Clin Pract, 78:149-58.
16. Hermansen K., Davies M, Derezinski T, et al. 2006. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care, 29:1269-74.
17. Hirsch I. B, Brownlee M. 2007. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes: response to author. Diabetes Care, 30(1):186-7.
18. Home P. and Kurtzhals P. 2006. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacoether, 7(3):325-43.
19. Home P., Boulton A, Jimenez J, et al. 2003. Issues relating to the early or earlier use of insulin in type 2 diabetes. Pract Diab Int, 20:61-73.
20. International Diabetes Federation (IDF). 2006. Diabetes Atlas, 3rd edition. p. 28-58.
21. Kilpatrick E. S, Rigby AS, Atkin SL. 2006. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care, 29(7):1486-90.
22. Klein O., Lygne J, Endahl L, et al. 2007. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab, 9(3):290-9.
23. Korytkowski M., Bell D, Jacobsen C, et al. for the Flexpen Study team. 2003. A multicenter, randomized, open-label, comparative, twoperiod crossover trial of preference, efficacy and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or type 2 diabetes mellitus. Clin Ther, 25(11):2836-48.
24. Korytkowski M., Niskanen L, Asakura T. 2005. Flexpen: addressing issues of confidence and convenience in delivery. Clin Ther, 27(Suppl 2): S89-100.
25. Korytkowski M. 2002. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord, 26(Suppl 3):S18-24.
26. Kurtzhals P., Havelund S, Jonassen I, et al. 1997. Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J Pharm Sci, 86(12):1365-8.
27. Kurtzhals P., Schaffer L, Sorensen A, et al. 2000. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes, 49(6):999-1005.
28. Kurtzhals P. 2004. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes, 28(Suppl 2):S23-8.
29. Lepore M., Pampanelli S, Fanelli C, et al. 2000. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes, 49:2142-8.
30. Lteif A. N, Schwenk WF. 1999. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care, 22(1):137-40.
31. Lüddeke H. J, Sreenan S, Aczel S, et al. PREDICTIVE Study Group. 2007. PREDICTIVE-a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab, 9(3):428-34.
32. Meneghini L., Koenen C, Weng W, et al. 2007. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patientswith type 2 diabetes-results of the randomized, controlled PREDICTIVE™ 303 study. Diabetes Obes Metab, 9:902-13.
33. Monnier L., Colette C, Leiter L, et al. on behalf of the PGR group. 2007. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes: response to author. Diabetes Care, 30(1):185-6.
34. Muggeo M., Zoppini G, Bonora E, et al. 2000. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care, 23(1):45-50.
35. Nathan D., Buse J, Davisdson M, et al. 2006. Management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care, 29:1963-72.
36. Niskanen L., Virkamäki A, Hansen JB, et al. 2008. Reducing fasting blood glucose variability is associated with a lower incidence of nocturnal hypoglycaemic events after starting insulin detemir: 3 month PREDICTIV™ data from 11 European countries. [abstract] Diabetologia, 51(Suppl 1):S388.
37. Peyrot M., Rubin RR, Lauritzen T, et al. on behalf of the International DAWN Advisory Panel. 2005. Resistance to insulin therapy among patients and providers results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care, 28:2673-9.
38. Philis-Tsimikas A, Charpentier G, Clauson P, Martinez Ravn G, Roberts VL, Thorsteinsson B. 2006. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther, 28:1569-81.
39. Polonsky W. H, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. 2005. Psychological insulin resistance in patients with type 2 diabetes. Diabetes Care, 28:2543-5.
40. Rašlová K., Bogoev M, Raz I, et al. 2004. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract, 66(2):193-201.
41. Rosenstock J., Davies M, Home PD, et al. 2008. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia, 51(3):408-16.
42. Russell-Jones D, Khan R. 2007. Insulin-associated weight gain in diabetes-causes, effects and coping strategies. Diabetes Obes Metab, 9(6):799-812.
43. Selam J. L, Koenen C, Weng W, et al. 2008. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin, 24(1):11-20.
44. Sommavilla B., Jørgensen C, Jensen KH. 2008. Safety, simplicity and convenience of a modified prefilled insulin pen. Expert Opin Pharmacother, 9(13):2223-32.
45. United Kingdom Prospective Diabetes Study; UKPDS 33. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet, 352:837-53.
46. United Kingdom Prospective Diabetes Study; UKPDS 35. 2000. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 321:405-12.
47. WHO. World Health Organization. Accessed July 2008. URL: www. who.org.